Trial Information

Summary: Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer

The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.

Inclusion Criteria

• Diagnosis of hepatocellular carcinoma (HCC) = 2cm based on:
• Biopsy OR
• Radiological evidence of HCC by contrast-enhanced CT scan or contrast-enhanced AND
• Blood test positive for Hepatitis B or C AND
• Alpha fetoprotein above > 400mg/L
• Not appropriate for curative surgery
• Screening blood pressure < 150/100mmHg, left ventricular ejection fraction (LVEF) > 45%

Exclusion Criteria

• Heart attack within 12 months, uncontrolled chest pain within 6 months
• Ascites resistant to diuretic medication therapy
• Portal-systemic encephalopathy (disease of the brain)
• Portal hypertension with bleeding esophageal or gastric varices within the past 2 months
• Deficiency of sodium in the blood with sodium < 125mEq/L

For more information,

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:29:38 AM